NeuroPace, Inc.
$16.53
▲
4.12%
2026-04-21 08:27:01
www.neuropace.com
NGM: NPCE
Explore NeuroPace, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$545.07 M
Current Price
$16.53
52W High / Low
$18.98 / $7.56
Stock P/E
—
Book Value
$0.57
Dividend Yield
—
ROCE
-18.62%
ROE
-1.59%
Face Value
—
EPS
$-0.66
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Devices
Employees
209
Beta
1.88
Debt / Equity
372.22
Current Ratio
5.28
Quick Ratio
4.33
Forward P/E
-40.36
Price / Sales
4.8
Enterprise Value
$489.87 M
EV / EBITDA
-30.43
EV / Revenue
4.9
Rating
Strong Buy
Target Price
$19.88
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Leverage is relatively high.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Xtant Medical Holdings, Inc. | $0.5 | 15.1 | $75.1 M | — | 11.26% | 10.59% | $0.95 / $0.39 | $0.36 |
| 2. | Varex Imaging Corporation | $11.97 | — | $501.54 M | — | 7.18% | -12.9% | $14.56 / $6.76 | $11.38 |
| 3. | Pulmonx Corporation | $1.42 | — | $59.98 M | — | -49.13% | -77.19% | $5.46 / $1.13 | $1.3 |
| 4. | Owlet, Inc. | $5.82 | — | $163.61 M | — | -19.96% | -8.02% | $16.94 / $3.08 | $0.71 |
| 5. | Sera Prognostics, Inc. | $2.29 | — | $90.03 M | — | -46.95% | -51.83% | $4.09 / $1.37 | $1.94 |
| 6. | LivaNova PLC | $65.81 | — | $3.6 B | — | 11.09% | -19.24% | $71.92 / $34 | $21.96 |
| 7. | Bio-Rad Laboratories, Inc. | $302.22 | 10.88 | $8.04 B | — | 2.17% | 10.84% | $343.12 / $211.43 | $276.16 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 26.59 M | 27.35 M | 23.52 M | 22.52 M | 21.47 M |
| Operating Profit | -1.77 M | -2.6 M | -6.82 M | -5.15 M | -3.65 M |
| Net Profit | -2.73 M | -3.5 M | -8.65 M | -6.59 M | -5.25 M |
| EPS in Rs | -0.08 | -0.1 | -0.26 | -0.2 | -0.16 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 99.99 M | 79.91 M | 65.42 M | 45.52 M |
| Operating Profit | -16.34 M | -21.67 M | -27.17 M | -40.79 M |
| Net Profit | -21.46 M | -27.14 M | -32.96 M | -47.08 M |
| EPS in Rs | -0.64 | -0.81 | -0.98 | -1.4 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 105.56 M | 94.65 M | 107.65 M | 114.11 M |
| Total Liabilities | 86.53 M | 86.63 M | 87 M | 79.33 M |
| Equity | 19.03 M | 8.01 M | 20.65 M | 34.78 M |
| Current Assets | 94.07 M | 81.34 M | 92.72 M | 97.71 M |
| Current Liabilities | 17.81 M | 15.16 M | 16.23 M | 10.98 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -11.01 M | -17.95 M | -19.7 M | -36.87 M |
| Investing CF | -0.33 M | 8.99 M | 23.03 M | 23.8 M |
| Financing CF | 19.6 M | 4.33 M | 8.13 M | 0.49 M |
| Free CF | -11.34 M | -18.25 M | -19.87 M | -37.47 M |
| Capex | -0.33 M | -0.31 M | -0.17 M | -0.6 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 22.14% | 43.72% | — | — |
| Earnings Growth % | 17.64% | 30% | — | — |
| Profit Margin % | -33.97% | -50.38% | -103.43% | — |
| Operating Margin % | -27.12% | -41.54% | -89.62% | — |
| Gross Margin % | 73.94% | 73.56% | 71.38% | — |
| EBITDA Margin % | -20.74% | -34.9% | -80.33% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.